BrightGene Bio-Medical Technology (SHA:688166) subsidiary Aitemei (Suzhou) Pharmaceutical Technology received a drug registration certificate from China's National Medical Products Administration for its tiotropium bromide inhalation spray.
The drug is indicated for chronic obstructive pulmonary disease, chronic bronchitis and emphysema, and dyspnea, according to a Saturday filing with the Shanghai bourse.
Global sales of the drug, first developed by Boehringer Ingelheim, reached $1.67 billion in 2025, according to market data cited in the filing.
Shares rose 5% during afternoon trading on Monday.